Small Cell Lung Cancer - Amgen 20240092

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT06745323?id=20240092&limit=10&sort=@relevance&rank=1

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut

Contacts: Sierra Cugno: Sierra.Cugno@hhchealth.org; Siobhan Reilly: Siobhan.Reilly@hhchealth.org